AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase II clinical study titled Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy. The study aims to evaluate the efficacy and safety of combining durvalumab and bevacizumab with transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) that can be treated with embolization. This study is significant as it explores a potential new treatment option for HCC, a challenging cancer to treat.
The intervention involves an experimental combination of two drugs, Durvalumab and Bevacizumab, administered intravenously, alongside a procedure called Transarterial Radioembolization (TARE) using Yttrium-90 glass microspheres. This combination aims to enhance the treatment efficacy for patients with HCC.
The study is designed as an interventional, single-group assignment with no masking, focusing primarily on treatment. Approximately 125 participants will be enrolled across 20 sites in the US, targeting those eligible for locoregional therapy but not for surgical resection or liver transplant.
The study officially started on February 13, 2024, with a primary completion date yet to be determined. The latest update was submitted on July 18, 2025. These dates are crucial as they mark the progress and timelines for potential results and subsequent market implications.
The study’s progress could influence AstraZeneca’s stock performance, as positive outcomes may boost investor confidence and position the company favorably against competitors in the oncology sector. The ongoing research highlights AstraZeneca’s commitment to expanding its oncology portfolio, potentially impacting market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.